Developing “Bioelectronics Medicines”
Glaxo Smith Klein’s R&D center at Stevenage, UK and Verify Life Science’s innovation group in South San Francisco have announced their collaboration creating a new company, Galvani Bioelectronics, headquartered in Stevenage. Quoting directly from the news release: “Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices.” Stay tuned. MORE